There is building evidence that novel combination therapies could be effective in treating early relapsed multiple myeloma.
Kyle Doherty
Advertisement
Kyle Doherty joined MJH Life Sciences in 2021 and is the lead editor for Oncology Fellows. He also produces print content for OncologyLive, as well as news and conference updates for OncLive.com. Email: [email protected]
Articles by Kyle Doherty
February 23, 2021 - AbbVie and Caribou Biosciences, Inc have entered into a collaboration and license agreement for the research and development of chimeric antigen receptory T-cell therapeutics.
January 29, 2021 - Dana-Farber Cancer Institute has announced the launch of its first-ever venture fund, Binney Street Capital, LLC.
Advertisement
Advertisement
Advertisement
Trending on OncLive
1
Mocertatug Rezetecan Drives Rapid, Deep Responses in Platinum-Resistant Ovarian and Recurrent/Advanced Endometrial Cancer
2
Trastuzumab Pamirtecan Provides Meaningful Survival Benefit in Pretreated HER2-Expressing Endometrial Cancer
3
Bulumtatug Fuvedotin Yields 32% ORR as First Nectin-4 ADC With Data in Cervical Cancer
4
Enzalutamide Decreases Cognitive Function Vs Darolutamide in Prostate Cancer
5